19 results about "Pentamer" patented technology

The invention discloses an arginine decarboxylase diaA enzyme mutant and application thereof in preparation of butanediamine, and belongs to the field of bioengineering. According to the invention, rational charge overturning transformation is simultaneously carried out on a pentamer meridian oligomeric interface and a dimer latitudinal oligomeric interface, so that stable assembly and efficient catalysis of the decamer under the condition of neutral to alkaline pH (7.0-9.0) are realized. Wherein positive charges are introduced into a meridian interface to weaken electrostatic repulsion, and negative charges are introduced into a latitudinal interface to enhance dimer compactness and substrate transfer efficiency. The specific enzyme activity of the representative double mutant AdiAD110K / H736E at pH 8.0 is about 35 times that of a wild type, and the representative double mutant AdiAD110K / H736E keeps a complete decamer state in a pH range of 7.0-9.0. The yield of butanediamine is up to 145.9 g / L under the whole-cell catalysis of the mutant.

The invention discloses a rational copolymerization strategy for improving the stability of an oligomeric structure of acid-induced high-order oligomeric decarboxylase AdiA in a neutral to alkaline environment and application of the rational copolymerization strategy, and belongs to the field of bioengineering. According to the strategy, rational charge overturning transformation is carried out on a pentamer radial oligomeric interface and a dimer weft-wise oligomeric interface at the same time, and stable assembly and efficient catalysis of a decamer under the condition that the pH value is from 7.0 to 9.0 from neutral to alkaline are achieved. Wherein positive charges are introduced into a meridian interface to weaken electrostatic repulsion, and negative charges are introduced into a latitudinal interface to enhance dimer compactness and substrate transfer efficiency. The specific enzyme activity of the representative double mutant AdiAD471K / E467K / H736E is 45.5 times that of a wild type when the pH value is 8.0, and the representative double mutant AdiAD471K / E467K / H736E keeps a complete decamer state when the pH value is 7.0-9.0. The yield of butanediamine is up to 156.5 g / L by using the mutant to catalyze whole cells.

This invention discloses a method for rapidly constructing a complex of cholera toxin B subunit (CTB) and antigen. The vaccine complex includes a CTB-SpyTag fusion protein and at least one SpyCatcher-antigen fusion protein. It also includes a preparation method for rapidly preparing a CTB5-antigen complex by mixing CTB-SpyTag with the SpyCatcher-antigen. This invention directs the antigen to the side of the CTB pentamer that does not participate in GM1 binding, avoiding steric hindrance interference. It utilizes the SpyTag / SpyCatcher covalent isopeptide bond to obtain highly stable antigen display, reducing antigen shedding during subsequent preparation and storage. It also possesses mucosal targeting and multivalent presentation functions, providing a universal platform technology for rapidly constructing and validating broad-spectrum, combined, or personalized mucosal vaccines.

This invention relates to de novo-designed voltage-gated anion channel proteins and their applications. The de novo-designed voltage-gated anion channel proteins (dVGACs) have a funnel-shaped pentamer structure, wherein each monomer in the pentamer consists of three transmembrane helices, and the amino acid sequence of each monomer includes SEQ ID No.:1 or a mutant thereof, wherein the amino acid sequence of the mutant is mutated to at least arginine or aspartic acid at positions 43, 47, 51, and 55 of SEQ ID No.:1. The dVGACs of this invention are selective for chloride ions and exhibit voltage-responsive conformational changes, leading to the opening of the central pore at membrane potentials of approximately +40 mV or +20 mV and above. Due to these properties, they have broad application prospects in the treatment of neurological diseases, regulation of cell behavior, and the development of biosensors.

The application relates to the technical field of autoimmune disease in vitro diagnosis, and particularly relates to a recombinant expression vector for inducing expression of clustered acetylcholine receptors, a double-stable cell strain and application thereof. The recombinant expression vector is a tetracycline-inducible expression vector for single-carrier multi-subunit independent expression; the vector is integrated with acetylcholine receptor full-subunit coding sequence and Rapsyn protein coding sequence through an iterative enzyme cutting-linking mode, wherein each to-be-inserted subunit independent expression box is respectively provided with I-CeuI enzyme cutting sites and BstXI enzyme cutting sites at two ends, and each subunit and Rapsyn protein are driven to express by an independent Tet-On inducible promoter after iterative linking. Through the core design of single-carrier multi-subunit independent expression and Tet-On tetracycline induction regulation, the acetylcholine receptor pentamer assembly efficiency, the stable cell strain passage stability and the anti-AChR antibody detection performance are greatly improved.

This invention provides a material for detecting serum plasma anti-nicotinic acetylcholine receptor antibodies and its method of use. The material comprises HEK293T cells transfected with three recombinant expression plasmids: the first plasmid encodes a truncated AChR α subunit; the second plasmid is a polycistronic plasmid encoding a fusion protein composed of a truncated AChR β subunit, an AChR δ subunit, and rapsyn protein linked by a P2A peptide; and the third plasmid encodes a truncated AChR γ subunit or ε subunit. After co-transfection with PEI, the cells are cultured in fresh complete medium for 25-35 hours after 7-9 hours post-transfection, followed by fixation, blocking, and preservation. This invention, through a three-plasmid system and antigen truncation modification, reduces cytotoxicity while ensuring high expression of the functional pentamer, significantly improving detection sensitivity and reagent shelf life.

This document provides a recombinant polypeptide comprising an engineered extracellular domain of a respiratory syncytial virus (RSV) fusion (F) protein, wherein the extracellular domain comprises an engineered C-terminal α-helical region and / or amino acid substitutions, the amino acid substitutions stabilizing the F protein in its pre-fusion conformation. This disclosure also provides a two-component protein nanostructure comprising a first trimer component and a second pentamer component. This document provides a composition for use in vaccination, inducing an immune response, or treating or preventing RSV disease.

An expression vector for producing a target protein-fused pentamer of the present invention includes a polynucleotide that encodes a pentameric toxin protein and a viral nucleocapsid as fusion partners of a target protein. In addition, a method of producing a target protein-fused pentamer of the present invention includes manufacturing an expression vector for producing a target protein-fused pentamer, which includes a polynucleotide that encodes a target protein and a pentameric toxin protein and a viral nucleocapsid as fusion partners of the target protein; producing a transformant by introducing the expression vector for producing a target protein-fused pentamer into host cells; and culturing the transformant.

This invention relates to a method for the catalytic preparation of 1,5-pentamethylene diisocyanate trimer, belonging to the field of organic synthesis and polymer materials technology. Addressing the problems of poor catalyst selectivity and the tendency to generate pentamers and higher polymers in existing PDI trimer synthesis processes, leading to increased product viscosity and decreased NCO content, this invention proposes using potassium isooctanoate catalyst under nitrogen protection. The purified PDI monomer is heated to 90°C, and 0.8‰ (based on the mass of PDI monomer) of catalyst is rapidly added dropwise. The reaction is controlled until the NCO conversion reaches 30%, then a terminator is added to terminate the reaction, followed by molecular distillation to remove residual monomers. Gel permeation chromatography (GPC) analysis shows that the obtained product contains 29.46% trimer, and the contents of pentamers, heptamers, and high polymers (n≥9) are 5.74%, 2.12%, and 5.90%, respectively. This invention achieves highly selective synthesis of PDI trimer, producing a product with low viscosity and high NCO content, which can be used as a curing agent for high-performance polyurethane coatings and has promising industrial application prospects.

The application discloses an arginine decarboxylase adiA enzyme mutant and application thereof in preparation of butanediamine, and belongs to the field of bioengineering.The application realizes stable assembly and efficient catalysis of a tenmer under neutral to alkaline pH (7.0-9.0) conditions by simultaneously performing rational charge flip modification on a pentamer cyclohexane oligomer interface and a dimer weft oligomer interface. In the application, positive charges are introduced into the cyclohexane interface to weaken electrostatic repulsion, and negative charges are introduced into the weft interface to enhance the dimer tightness and substrate transport efficiency. A representative double mutant AdiA D110K / H736E The specific enzyme activity is about 35 times that of the wild type at pH 8.0, and the tenmer state is maintained in the range of pH 7.0-9.0. The butanediamine yield reaches 145.9 g / L by using the mutant whole cell catalysis.

An object of the present invention is to provide an effective vaccine that can prevent and treat infection with CMV. A fusion protein of the present invention is a fusion protein of envelope glycoprotein B (gB protein) and a pentamer of the cytomegalovirus (CMV). A vaccine for prevent or treat infection with cytomegalovirus (CMV) of the present invention is a subunit vaccine containing a fusion protein of envelope glycoprotein B (gB protein) and a pentamer of CMV as an antigen.

The invention belongs to the technical field of biological medicines, and particularly relates to a method for preparing a pentamer by taking HPV-VLPs as a substrate. The invention provides a method for preparing a pentamer by taking HPV-VLPs expressed by an eukaryotic expression system as a substrate, the method is simple and efficient, and a thought is provided for an eukaryotic expression route process and a verification method; the eukaryotic pentamer prepared by the method provides a key material for carrying out eukaryotic pentamer research and developing HPV vaccines.

A method of producing a monomer of a Shiga toxin B-subunit (STxB) protein or of a variant thereof by peptide chemical synthesis, as well as to a method of producing a pentamer of the STxB protein or of the variant thereof. The methods are particularly advantageous as they overcome major issues typically observed in peptide chemical synthesis, including solubility and purity issues.

This invention relates to the field of biopharmaceutical technology, specifically to a recombinant pentamer protein, polynucleotide, expression vector, host cell, preparation method, and application. The fusion protein is formed by fusing LTB or its immunogenic functional variant with the pentamer domain of COMP via a flexible linker peptide. This invention constructs the gene of this fusion protein in a eukaryotic expression vector, transfects it into CHO-K1 cells, obtains stable high-expression cell lines through pressure selection, and performs efficient secretory expression using serum-free suspension culture. The resulting protein forms a pentamer under non-reducing conditions. The sIgA level in mouse nasal lavage fluid is significantly higher than that of the antigen alone, confirming its effective activation of local immunity in the respiratory mucosa. This invention utilizes the CHO expression system to achieve large-scale preparation of structurally correct, homogeneous, and endotoxin-free LTB pentamers, which has significant application value in the development of mucosal vaccines, targeted delivery, and diagnostic reagents.

The application provides a hawthorn condensed tannin polymer and a preparation method and application thereof. The hawthorn condensed tannin polymer is extracted from hawthorn pulp, and the hawthorn condensed tannin polymer comprises a mixture of dimers, trimers, tetramers, pentamers, hexamers, heptamers, octamers, nonamers, decamers, undecamers, dodecamers, tridecamers, tetradecamers, pentadecamers, hexadecamers, heptadecamers and octadecamers of epicatechin shown in formula (I). Wherein, n is a positive integer between 2 and 18, and at least one of the dimers, trimers, tetramers, pentamers, hexamers, heptamers, octamers, nonamers, decamers, undecamers, dodecamers, tridecamers, tetradecamers, pentadecamers, hexadecamers, heptadecamers and octadecamers comprises a B-type procyanidin polymer obtained by connecting epicatechin structural units through C4-C8 or C4-C6.

The application discloses a kind of multimeric antigens and preparation method thereof, wherein the multimeric antigen is formed by self-assembly of fusion protein, and the fusion protein includes capsid protein and C-reactive protein.The multimeric antigen in the application is virus-like particle structure, and the C-reactive protein is located on the outside of the virus-like particle structure.The multimeric antigen in the application is a icosahedral multimeric particle, which partially simulates the spatial site of natural antigen pentamer, and improves the recognition efficiency of the generated antibody to natural antigen.

Described are mutant human cytomegalovirus (HCMV) pentamer complex polypeptides, methods of making them, and their use in HCMV protein complexes and compositions. In particular, the use of the modified HCMV polypeptides to stabilize HCMV complexes or unmask a pentamer epitope is described.

The invention provides a method for enhancing plant disease resistance based on rice disease-resistant PTR protein and application. The rice disease-resistant PTR protein is an endoplasmic reticulum positioned pentamer Ca < 2 + > channel, the C terminal of the rice disease-resistant PTR protein comprises a self-inhibition structural domain, the structural domain contains a CaaX motif (CCIS), and C902-site cysteine is subjected to farnesylation modification so as to maintain the inactivation state of the channel. According to the present invention, the pyricularia grisea effect protein AVR-Pita specifically recognizes and cuts the site (PEPPA / KPEP) between the 874th alanine (A874) and the 875th lysine (K875) of the PTR, and a self-inhibition module is removed so as to activate the Ca < 2 + > channel activity, release the Ca < 2 + > of the endoplasmic reticulum to the cytoplasm, and further trigger the immune response; the method can be widely applied to disease-resistant breeding of rice and other crops, and has good application prospects and industrial value.

An embodiment of the present specification provides an iron isomaltose anhydride complex comprising iron oxyhydroxide and isomaltose anhydride stably associated with the iron oxyhydroxide, the content of pentamer saccharides in the isomaltose anhydride being about 16% to about 25% based on the total weight of the isomaltose anhydride, the hexamer saccharide content is from about 14% to about 23%, and the tetramer saccharide content is from about 9% to about 17%.